Results 21 to 30 of about 18,311 (150)

Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma

Cancers, 2023
Simple Summary Immune check point inhibitors (ICPIs) are one of the treatment options for advanced hepatocellular carcinoma (HCC). No biomarker is currently available to upfront select patients to be addressed to one or another drug.
C. Giovannini, F. Suzzi, F. Tovoli, M. Bruccoleri, Mariarosaria Marseglia, E. Alimenti, F. Fornari, M. Iavarone, F. Piscaglia, L. Gramantieri   +9 more
semanticscholar   +1 more source

Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice

Nature Microbiology
Bacteria such as the oral microbiome member Peptostreptococcus anaerobius can exacerbate colorectal cancer (CRC) development. Little is known regarding whether these immunomodulatory bacteria also affect antitumour immune checkpoint blockade therapy ...
Yali Liu, C. Wong, Yanqiang Ding, Mengxue Gao, Jun Wen, H. C. Lau, A. H. Cheung, Dan Huang, He Huang, Jun Yu   +9 more
semanticscholar   +1 more source

Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain

Experimental Hematology & Oncology, 2023
Background Immunosuppression induced by programmed cell death protein 1 (PD1) presents a significant constraint on the effectiveness of chimeric antigen receptor (CAR)-T therapy. The potential of combining PD1/PDL1 (Programmed cell death 1 ligand 1) axis
A. Zhang, Shenyu Wang, Yao Sun, Yikun Zhang, Long Zhao, Yang Yang, Yijian Zhang, Lei Xu, Yangyang Lei, Jie Du, Hu Chen, Lian Duan, Mingyi He, Lintao Shi, Lei Liu, Quanjun Wang, Liang-ding Hu, Bin Zhang   +17 more
semanticscholar   +1 more source

Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma

Nature Communications
Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma.
Jia-Cheng Lu, Lei-Lei Wu, Yi-Ning Sun, Xiao-yong Huang, Chao Gao, Xiaoen Guo, H. Zeng, Xu-Dong Qu, Yi Chen, Dong Wu, Yan-Zi Pei, Xiangjing Meng, Yi-Min Zheng, Chen Liang, Peng-Fei Zhang, Jia-Bin Cai, Zhen–Bin Ding, Guo-huan Yang, Ning Ren, Cheng Huang, Xiao-Ying Wang, Qiang Gao, Qi-man Sun, Yinghong Shi, S. Qiu, A. Ke, G. Shi, Jian Zhou, Yidi Sun, Jia Fan   +29 more
semanticscholar   +1 more source

Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1

Frontiers in Pharmacology, 2023
Anti-PD1/PDL1 monotherapy has failed to acquire sufficiently ideal results in most solid tumors. Mesenchymal stem cells (MSCs) have been reported to exert therapeutic effects on some tumors, but the functions of MSCs in colorectal cancer (CRC) need ...
Jize Liu, Xiaomin Ma, Chuxuan Liu, Yang Cheng, Bingjun Li, W. Zhang, Runzhi Zeng, Qi-sheng Chen, Yun Zhang, Sanyuan Hu   +9 more
semanticscholar   +1 more source

Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor

Oncoimmunology, 2023
Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated success in the treatment of hematological malignancies; however, its efficacy and applications in solid tumors remain limited.
Jingjing Zhao, Jiebin Dong, Changwen Deng, Qianjing Zhang, Shicheng Sun, Honggang Li, Yun Bai, Hongkui Deng   +7 more
semanticscholar   +1 more source

FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer

Cell Death and Disease
Programmed cell death 1 ligand 1 (PDL1)/programmed cell death 1 (PD1) blockade immunotherapy provides a prospective strategy for the treatment of colorectal cancer (CRC), but various constraints on the effectiveness of the treatment are still remaining ...
Haiyang Li, Na Zheng, Anning Guo, Weiwei Tang, Mu-Xing Li, Yuanyuan Cao, Xinhua Ma, Hongyong Cao, Yong Ma, Hanjin Wang, Shuli Zhao   +10 more
semanticscholar   +1 more source

HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy

Journal of Clinical Investigation, 2022
Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide and available therapies, including immunotherapies, are ineffective for many patients.
Shaima Salman, D. Meyers, Elizabeth E. Wicks, S. N. Lee, Emmanuel Datan, Aline M. Thomas, Nicole M. Anders, Yousang Hwang, Yajing Lyu, Yongkang Yang, Walter Jackson, Dominic Dordai, M. Rudek, G. Semenza   +13 more
semanticscholar   +1 more source

Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1

Journal of experimental & clinical cancer research : CR, 2022
Background Although success was achieved in the therapy for a minority of advanced lung adenocarcinoma (LUAD) patients, anti-programmed death 1 (PD1) resistance was found in most LUAD patients.
Jian Gao, Yongqiang Ao, Ling Zhang, Jie Deng, Shuai Wang, Haikun Wang, Jiapeng Jiang, Jian-Yong Ding   +7 more
semanticscholar   +1 more source

CD38–RyR2 axis–mediated signaling impedes CD8+ T cell response to anti-PD1 therapy in cancer

Proceedings of the National Academy of Sciences of the United States of America
Significance The success of immunotherapy relies on understanding the resistance mechanisms that impede the ability of T cells to respond to therapy. Phenotypic, functional, and single-cell transcriptomic analysis of intratumoral CD8+ T cells from both ...
Anwesha Kar, Puspendu Ghosh, A. Gautam, Snehanshu Chowdhury, Debashree Basak, Ishita Sarkar, A. Bhoumik, Shubhrajit Barman, Paramita Chakraborty, Asima Mukhopadhyay, S. Mehrotra, Senthil Kumar Ganesan, Sandip Paul, S. Chatterjee   +13 more
semanticscholar   +1 more source